Serina Therapeutics (Serina Therapeutics) Net Margin % : 0.00% (As of Jun. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Serina Therapeutics's Net Income for the six months ended in Jun. 2023 was $2.47 Mil. Serina Therapeutics's Revenue for the six months ended in Jun. 2023 was $0.00 Mil. Therefore, Serina Therapeutics's net margin for the quarter that ended in Jun. 2023 was 0.00%.

The historical rank and industry rank for Serina Therapeutics's Net Margin % or its related term are showing as below:

SER' s Net Margin % Range Over the Past 10 Years
Min: -536.4 Med: -289.02 Max: -41.63
Current: -536.4

SER's Net Margin % is ranked worse than
65.63% of 1033 companies
in the Biotechnology industry
Industry Median: -162.58 vs SER: -536.40

Serina Therapeutics Net Margin % Historical Data

The historical data trend for Serina Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Serina Therapeutics Net Margin % Chart

Serina Therapeutics Annual Data

Trend

Dec21

Dec22

Net Margin %

-41.63

-536.40

Serina Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
Net Margin %	-	-282.00	-	-

Competitive Comparison of Serina Therapeutics's Net Margin %

For the Biotechnology subindustry, Serina Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Serina Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Serina Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Serina Therapeutics's Net Margin % falls into.

Serina Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Serina Therapeutics's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin	=	Net Income (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-2.682	/	0.5
	=	-536.40 %

Serina Therapeutics's Net Margin for the quarter that ended in Jun. 2023 is calculated as

Net Margin	=	Net Income (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	2.467	/	0
	=	%

Serina Therapeutics (AMEX:SER) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Serina Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Serina Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Serina Therapeutics (Serina Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806

Website

https://www.serinatherapeutics.com

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.

Serina Therapeutics (Serina Therapeutics) Headlines

From GuruFocus

Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse� for Advanced Parkinson's Disease

By Marketwired • 05-15-2024